Last reviewed · How we verify
Autologous Engineered Skin Substitute
Autologous Engineered Skin Substitute is a regenerative medicine that uses a patient's own cells to promote skin healing.
Autologous Engineered Skin Substitute is a regenerative medicine that uses a patient's own cells to promote skin healing. Used for Burns, wounds, and other skin injuries.
At a glance
| Generic name | Autologous Engineered Skin Substitute |
|---|---|
| Also known as | ESS-W |
| Sponsor | Amarantus BioScience Holdings, Inc. |
| Drug class | Regenerative medicine |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 2 |
Mechanism of action
This treatment involves taking a patient's own skin cells, expanding them in a laboratory, and then reapplying them to the affected area to stimulate the growth of new skin tissue. The goal is to create a functional skin substitute that can help repair damaged skin and promote wound healing.
Approved indications
- Burns, wounds, and other skin injuries
Common side effects
- Wound infection
- Skin graft rejection
Key clinical trials
- Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents (PHASE2)
- Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Children (PHASE2)
- Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Full-Thickness Skin Defects in Adults and Children (PHASE2)
- Phase III Study with an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents (PHASE3)
- Study of an Artificial Human Skin Medicine for Patients With Basal Cell Carcinoma Undergoing Reconstructive Surgery (PHASE2)
- Phase I Study for Autologous Dermal Substitutes and Dermo-epidermal Skin Substitutes for Treatment of Skin Defects (PHASE1)
- Safety and Efficacy Study of Autologous Engineered Skin Substitute to Treat Partial- and Full-Thickness Burn Wounds (PHASE2)
- Treatment of Cutaneous Ulcers With a Novel Biological Dressing (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: